Amgen (NASDAQ: AMGN) reported Q1 EPS of $4.17, $0.41 better than the analyst estimate of $3.76. Revenue for the quarter came in at $6.2 billion versus the consensus estimate of $5.98 billion.

"I am inspired by the many ways my colleagues at Amgen and others across the industry are stepping up to meet the greatest public health challenge of our lifetime," said Robert A. Bradway, chairman and chief executive officer. "We are committed to an uninterrupted supply of our medicines to patients; advancing potential new medicines to treat serious diseases, including COVID-19; making a difference in the communities where we live and work; and creating long-term value for shareholders."

GUIDANCE:

Amgen sees FY2020 EPS of $14.85-$15.60, versus the consensus of $15.42. 2020 total revenues guidance reaffirmed at $25.0-$25.6 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.